Medtronic PLC $MDT Shares Acquired by Capital Analysts LLC

Capital Analysts LLC lifted its holdings in shares of Medtronic PLC (NYSE:MDT) by 5.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 168,785 shares of the medical technology company’s stock after purchasing an additional 9,294 shares during the quarter. Capital Analysts LLC’s holdings in Medtronic were worth $13,204,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in MDT. Brighton Jones LLC raised its position in Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC lifted its holdings in shares of Medtronic by 9.6% in the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after purchasing an additional 381 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of Medtronic in the second quarter valued at about $299,000. Main Street Financial Solutions LLC grew its position in shares of Medtronic by 28.9% in the second quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock valued at $1,251,000 after purchasing an additional 3,218 shares during the last quarter. Finally, HUB Investment Partners LLC increased its stake in shares of Medtronic by 21.3% during the 2nd quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock worth $1,676,000 after purchasing an additional 3,376 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on MDT shares. Royal Bank Of Canada restated an “outperform” rating and set a $118.00 price objective on shares of Medtronic in a research report on Wednesday, September 2nd. Sanford C. Bernstein dropped their price target on Medtronic from $112.00 to $97.00 and set an “outperform” rating for the company in a research report on Thursday, June 4th. Robert W. Baird boosted their price target on Medtronic from $91.00 to $100.00 and gave the stock a “neutral” rating in a report on Wednesday, September 2nd. The Goldman Sachs Group reduced their price objective on Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $92.00 price objective on shares of Medtronic in a research note on Thursday, September 3rd. Nineteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and a consensus target price of $103.92.

Medtronic Stock Performance

Shares of MDT opened at $92.41 on Wednesday. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company’s 50 day simple moving average is $87.33 and its 200 day simple moving average is $85.21. The company has a market capitalization of $118.20 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 2.21 and a beta of 0.56. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. Medtronic’s revenue for the quarter was up 13.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, sell-side analysts predict that Medtronic PLC will post 5.96 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a $0.72 dividend. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.1%. Medtronic’s payout ratio is currently 70.94%.

About Medtronic

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.